Martha Rodriguez

Deferasirox (Exjade®), the Once-Daily Oral Iron Chelator, Demonstrates Safety and Efficacy in Patients with Sickle Cell Disease (SCD): 3.5-Year Follow-up.

E. Vichinsky, T. Coates, A. Thompson, 2008 .

Deferasirox (Exjade®) in Pediatric Patients with β-Thalassemia: Update of 4.7-Year Efficacy and Safety from Extension Studies

R. Galanello, A. Piga, G. Forni, 2008 .

SAT0619-HPR AN AUDIT OF GLUCOCORTICOID PRESCRIPTION IN PATIENTS WITH GIANT CELL ARTERITIS

R. Luqmani, L. O’neill, A. Awisat, 2020 .